Gross I
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Mead Johnson Symp Perinat Dev Med. 1988(33):37-41.
Postnatal surfactant therapy, antenatal glucocorticoid therapy and now antenatal combined hormone therapy with glucocorticoids and TRH all appear to be effective in reducing the incidence of RDS or in ameliorating the severity of this condition. There is also evidence from animal and human studies that a combination of hormone therapy and surfactant therapy is more effective than either therapy alone. If the current trials of combined hormone therapy for the prevention of RDS continue to produce encouraging results, it is likely that in the near future threatened premature delivery before 33 weeks will be treated with tocolytics and a combination of glucocorticoid and TRH therapy. This is likely to be followed with prevention or rescue surfactant therapy. These new approaches should have a major impact in reducing the mortality and morbidity associated with premature birth.
产后表面活性剂治疗、产前糖皮质激素治疗以及现在的产前糖皮质激素与促甲状腺激素联合激素治疗，似乎都能有效降低呼吸窘迫综合征（RDS）的发病率或减轻该病的严重程度。动物和人体研究也有证据表明，激素治疗与表面活性剂治疗联合使用比单独使用任何一种治疗方法都更有效。如果目前预防RDS的联合激素治疗试验继续产生令人鼓舞的结果，那么在不久的将来，33周前有早产风险的孕妇可能会接受宫缩抑制剂以及糖皮质激素与促甲状腺激素联合治疗。随后可能会进行预防性或抢救性表面活性剂治疗。这些新方法应该会对降低与早产相关的死亡率和发病率产生重大影响。
